The Scottish Medicines Consortium (SMC) has rejected rimonobant (Acomplia®) for use on the NHS in Scotland.
The recommendation states that the economic case has not been demonstrated.
Rimonobant has already been identified as having a lower place in therapy by the Midlands Therapeutic Review and Advisory Committee and it was previously recommended as a fourth line option when it was launched.
Hat tip: Prescribing Advice for GPs
The recommendation states that the economic case has not been demonstrated.
Rimonobant has already been identified as having a lower place in therapy by the Midlands Therapeutic Review and Advisory Committee and it was previously recommended as a fourth line option when it was launched.
Hat tip: Prescribing Advice for GPs
1 comment:
Ooch Eye the Noo!
Hew em I gonna ha' mi "battered deep fried Mars Bar" the Noo?
Benedict
Post a Comment